



#### FIFTH EDITION

# Jack S. Remington, M.D.

Professor of Medicine

Division of Infectious Diseases and Geographic Medicine

Stanford University School of Medicine

Stanford, California

Marcus A. Krupp Research Chair and Chairman

Department of Immunology and Infectious Diseases

Research Institute

Palo Alto Medical Foundation

Palo Alto, California

# Jerome O. Klein, M.D.

Professor of Pediatrics

Boston University School of Medicine

Vice Chairman for Academic Affairs

Department of Pediatrics

Maxwell Finland Laboratory for Infectious Diseases

Boston Medical Center

Boston, Massachusetts

0.2000

# W.B. Saunders Company

A Harcourt Health Sciences Company

Philadelphia London New York St. Louis Sydney Toronto



TESSA: GARDNER, M.D.

THE ORGANISM, 522

Borrelia burgdorferi as the Etiologic Agent of Lyme Borreliosis

Morphology

Molecular Biology

Taxonomy

Isolation and Cultivation

Antibiotic Susceptibility

Interactions with the Immune System

T Lymphocyte Reactivity

Development of Serum Antibody

Induction of Other Antibodies

Failure to Develop Serum Antibody

Development of Cerebrospinal Fluid Antibody

Interactions with Complement

Interactions with Phagocytes

Evasion of Host Defenses and Persistence in

Tissue

Correlation of Clinical Manifestations with HLA Type

EPIDEMIOLOGY AND TRANSMISSION, 535

Historical Review

Tick (and Other Arthropod) Vectors

Enzootic Cycles: Tick Vector Life Cycles and

Reservoir Animal Hosts

Seasonality of Human Tick Bites/Transmission of Borrelia burgdorferi Infection

Geographic Distribution of Tick Vectors

Geographic Distribution of Lyme Borreliosis

Geographic Distribution of Lyme Disease in North America

Expansion of Lyme-Endemic Areas in North

Geographic Distribution of Lyme Borreliosis

in Europe, Asia, and Other Continents Expansion of Lyme-Endemic Areas in Europe, Asia, and Other Continents

Lyme Borreliosis in Travelers to Endemic

Borrelia burgdorferi Tick Infection Rates Borrelia burgdorferi Reservoir Animal Infection

PATHOLOGY AND PATHOGENESIS, 552

Immunopathogenesis

Lyme Borreliosis in Pregnant and Nonpregnant Women

Cutaneous

Reticuloendothelial

Cardiac

Neurologic

Musculoskeletal

Lyme Borreliosis in the Fetus and Newborn

Infant

Cutaneous

Reticuloendothelial

Pulmonary

Cardiac

Neurologic

Musculoskeletal

Genitourinary

Infantile Multisystem Inflammatory Disease

Other Congenital Borrelial Infections

Relapsing Fever

CLINICAL MANIFESTATIONS, 558

Case Definition and Classification of Stages of

Lyme Borreliosis

Incidence of Lyme Borreliosis in Women of

Childbearing Age

Clinical Manifestations of Gestational and

Nongestational Lyme Borreliosis

Erythema Migrans

Borrelial Lymphocytoma

Arthritis

Neuroborreliosis

Carditis

Acrodermatitis Chronica Atrophicans

Other Organ Involvement in Disseminated Infection

Post-Lyme Syndromes

Reinfection with Borrelia burgdorferi Co-infection with Babesia or Ehrlichia

Clinical Manifestations of Congenital Lyme

Borreliosis

Congenital and Gestational Lyme Borreliosis

Review of 66 Cases of Adverse Outcomes of Gestational Lyme Borreliosis

Frequency of Specific Adverse Outcomes of

Gestational Lyme Borreliosis

Frequency of Adverse Outcomes of 263 Cases

of Gestational Lyme Borreliosis

Effect of Trimester of Infection

Effect of Gestational Antibiotic Therapy

Rate of Miscarriage and Stillbirth

Rate of Neonatal Death

Rate of Neonatal Illness

Description of Congenital Lyme Borreliosis Asymptomatic Infant with Gestational Lyme

Borreliosis Exposure

Mild Early Congenital Lyme Borreliosis

Severe Early Congenital Lyme Borreliosis

Late Congenital Lyme Borreliosis

DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS, 585

Diagnostic Tests

Culture

Silver and Immunofluorescent Stains

Dark-field Examination

Polymerase Chain Reaction

Immunofluorescent Assay

Enzyme-Linked Immunosorbent Assay

Antibody Capture ELISA, Immune-Complex

ELISA, and Antibody Capture Immune-Complex Biotinylated ELISA

Western Blot (Immunoblot)

Lymphocyte Proliferative Assay

Antigen Capture ELISA Assay

Laboratory Variability and Efforts at

Serodiagnostic Standardization Avoidance of Over- or Underdiagnosis

Recommendations for Diagnostic Testing for Evaluation of Nongestational, Gestational,

and Congenital Lyme Borreliosis

Differential Diagnosis of Lyme Borreliosis

Differential Diagnosis of Congenital Lyme

Borreliosis

THERAPY, 601

Antibiotic Therapy Efficacy Trials

Erythema Migrans, Borrelial Lymphocytoma, and Acrodermatitis Chronica Atrophicans

Lyme Arthritis

Lyme Carditis

Neuroborreliosis

Achievement of Serum and CSF Antibiotic Levels Above the Borrelia burgdorferi Minimal Inhibitory Concentration

Jarisch-Herxheimer Reaction and Other Antibiotic Therapy Side Effects

Correlation Between Antibiotic Therapy and Outcome of Gestational and Congenital Lyme Borreliosis

Review of Recommendations for Antibiotic

Therapy of Gestational Lyme Borreliosis Recommendations for Antibiotic Therapy of

Gestational, Nongestational, and

Congenital Lyme Borreliosis Predictors of Antibiotic Therapy Cure

PREVENTION, 612

Tick Vector and Animal Reservoir/Host Control Measures

Animal Models

Vaccine Development

Recreational and Occupational Lyme

Borreliosis Risk, and Methods for

Individual Protection Against Tick Bites

Antibiotic Prophylaxis of Tick Bites in Pregnant and Nonpregnant Patients

Educational Programs to Increase Lyme

Disease Awareness

PROGNOSIS, 619

Lyme disease, or Lyme borreliosis, is a tickborne zoonosis of both children and adults caused by the spirochete Borrelia burgdorferi.1, 2 It has a worldwide geographic distribution and has been reported from more than 40 countries and 6 continents; the geographic distribution and number of cases reported continue to increase (Figs. 11-1 and 11-2). It is now the most common tickborne infection in the United States,3-6 where 16,800 cases were reported to the Centers for Disease Control and Prevention (CDC) in 1998 (Fig. 11-3); in Europe,8-10 where 2100 cases were reported to the European Union Concerted Action of Risk Assessment in Lyme Borreliosis (EUCALB) in 1994, and more than 60,000 cases were estimated to occur annually as of 19989; and possibly in the world.11-13

Lyme borreliosis is a fairly recently recognized infection, although erythema migrans (EM), the characteristic skin lesion of early Lyme borreliosis, was first described in a Swedish woman in 1909 by Afzelius, who proposed that it was related to a zoonosis transmitted by a tick bite.14 In 1975, Steere and associates recognized an outbreak of infectious arthritis and unusual rash similar to European EM in Old Lyme, Connecticut; they proposed that transmission occurred via an arthropod vector and named the disease Lyme arthritis.15 Eventually, it was found to be associated with ixodid tick bites and later, when its multisystem involvement was recognized, became known as Lyme disease.

In 1981, Burgdorfer and colleagues discovered a new species of Borrelia in Ixodes ticks associated with Lyme disease, and this became known as Borrelia burgdorferi.1. 16, 17 This spirochete was found to be the causative agent of North American Lyme disease18 and of European EM,19 as well as other European syndromes such as acrodermatitis chronica atrophicans (ACA),20 Bannwarth's syndrome,21 and lymphadenosis benigna cutis22; the entire disease complex is now known as Lyme borreliosis.

As worldwide reporting of Lyme borreliosis increases, a geographically defined "Lyme Belt" is emerging between 30 and 65 degrees North latitude in the Eastern Hemisphere, and between 25 and 50 degrees North latitude in the Western Hemisphere; there may also be a belt developing between 30 and 40 degrees South latitude in the Eastern Hemisphere. This is reminiscent of the "Malaria Belt," which has been defined by climatic conditions and the distribution of another major arthropod vector of human disease, the Anopheles mosquito.




FIGURE 11-1 A, The geographic distribution of Lyme borreliosis in Europe. Europe is the main area outside North America from which Lyme borreliosis has been reported. This map shows European countries from which cases of Lyme borreliosis have been reported either to the World Health Organization, 501 to the European Union Concerted Action on Risk Assessment in Lyme Borreliosis, 9, 10 or in the medical literature, 11, 12, 41-44, 48, 83, 85-87, 90, 162, 251, 268, 275, 276, 306, 310, 352, 370, 381, 381, 387, 380, 402-405, 409, 422, 432-435, 448, 503, 504, 507-523, 525-537, 539-550, 552, 553 Reliable statistics on incidence by country are not available, as reporting of cases is voluntary in most countries. The highest incidences (either 1000-20,000 cases/country or 15-140 cases/100,000 population annually) of European Lyme borreliosis have been reported from Austria, Slovenia, Poland, Sweden, Bulgaria, Denmark, Hungary, the Netherlands, Finland, the Czech Republic, Switzerland, Germany, Italy, and France; lower incidences (either <500 cases/country, or <5 cases/100,000 population annually) have been reported from Belgium, Croatia, Estonia, Greece, Ireland, Latvia, Lithuania, Luxembourg, Moldavia, Norway, Romania, Russia, Spain, the United Kingdom, and the former Yugoslavia.

Illustration continued on following page

Lyme borreliosis is a multisystem infection that initially emerged as a new "great imitator"14 because of the diversity of its clinical presentations, which comprise both early and late stages and include dermatologic, cardiac, neurologic, arthritic, and ocular manifestations.23 However, more than 20 years since its recognition as a new disease,15 the spectrum of its clinical manifestations has been extensively characterized, resulting in gradual loss of this reputation.24 The existence of congenital borreliosis was suspected because of clinical similarities between the two spirochetoses Lyme borreliosis and the classic "great imitator" syphilis,599 and the well-known association of gestational syphilis with mis-

carriage, early congenital infection, and late congenital infection.

Maternal-fetal transmission of B. burgdorferi was first reported in 1985 by Schlesinger and co-workers.25 As the number of reported cases of Lyme disease continues to increase, there have been increasing reports of gestational Lyme disease associated with adverse outcomes and suspected congenital Lyme borreliosis.25-48 Although a homogeneous congenital Lyme borreliosis syndrome has not yet emerged, there are several features that are common among the 66 adverse outcomes of pregnancies complicated by gestational Lyme borreliosis reviewed later in this chapter (including miscarriage during the




FIGURE 11–1 Continued. B, The worldwide geographic distribution of Lyme disease in temperate zone "Lyme Belts." In addition to North America and Europe, Lyme borreliosis is also endemic in Asia, mainly in China and Japan, and it has been reported from countries on three other continents and the Caribbean, including Argentina, Australia, Brazil, Chile, Egypt, Honduras, Israel, Mexico, Mozambique, Puerto Rico, South Africa, Taiwan, and Tunisia, although some of these cases may not have been indigenously acquired. The existence of indigenous cases in Central and South America, the Caribbean, Australia, and central and southern Africa is still uncertain. 164, 165, 300, 344, 349-351, 374, 388, 499, 448, 449, 451-453, 455, 456, 506, 504-551, 563, 566-569 | Ixodid ticks infected with Borrelia burgdorferi have been found in Korea, and in several subarctic and subantarctic circumpolar islands (Egg and St. Lazaria Islands of Alaska, Flatey Island of Iceland, Campbell Island of New Zealand, and the Crozet Islands), but no cases of Lyme borreliosis have been reported yet from these areas. 165, 555 The geographic distribution of Lyme disease cases forms two belts—a 35-degree-wide northern temperate zone belt between 30 and 65 degrees North latitude in the Eastern Hemisphere, and another one slightly more southerly between 15 and 50 degrees North latitude in the Western Hemisphere. These include the majority of the Asian, European, North African, and North American cases. In addition, the cases from Australia, southern Africa, and South America appear to be clustered in a temperate zone belt between 10 and 40 degrees South latitude, but more cases are needed to determine if this is a true Southern Hemisphere "Lyme Belt."


first 20 weeks of gestation with a high frequency of fetal cardiac abnormality; severe early congenital infection with fulminant neonatal sepsis and meningoencephalitis and a high frequency of cardiac abnormality; mild early congenital infection with growth retardation and mild cardiac abnormality; and late congenital infection with growth retardation, developmental delay, and neurologic, cutaneous, dental, and skeletal involvement).

#### THE ORGANISM

Borrelia organisms are arthropod-borne spirochetes that infect birds, domestic and wild animals, and humans. 49.

50, 52 It is now recognized that *B. burgdorferi* is a phenotypically and genotypically heterogeneous genospecies complex, and the name has been modified to *Borrelia burgdorferi sensu lato* to reflect this. There are several genospecies of *Borrelia burgdorferi sensu lato*: *Borrelia burgdorferi sensu stricto*, *Borrelia andersonii*, *Borrelia garinii*, *Borrelia afzelii*, *Borrelia valaisiana*, *Borrelia lusitaniae*, *Borrelia japonica*, *Borrelia tanukii*, *Borrelia turdae*, and several genetically distinct genomic groups that have not yet achieved genospecies status. 51-71, 884 *B. burgdorferi sensu stricto*, *garinii*, and *afzelii* have been associated with human Lyme borreliosis 55; *B. valaisiana* DNA has been found in EM lesions of two patients by polymerase chain reaction (PCR)<sup>72</sup>; and strains similar to strain 25015 in

#### CASES OF LYME DISEASE REPORTED TO THE CDC IN 1982



#### CASES OF LYME DISEASE REPORTED TO THE CDC IN 1987




FIGURE 11-2 The increase in the number of cases and expansion of the geographic distribution of Lyme disease in the United States from 1982 through 1998. The number of cases of Lyme disease reported to the Centers for Disease Control and Prevention (CDC) by state health departments in (A) 1982, (B) 1987, and (C) 1998. A 461 National surveillance began in 1982, and Lyme disease became a notifiable disease in 1990. Cases of Lyme disease have also been reported to the Canadian Laboratory Centre for Disease Control (LCDC), mostly from southern areas that border Lyme-endemic areas of the northeastern, upper midwestern, and northwestern United States. 479

Illustration continued on following page






FIGURE 11-2 Continued

genomic group DN127 occasionally have been associated with Lyme disease. 83, 865 The other genospecies are involved in enzootic cycles of maintenance of B. burgdorferi in nature, but have not yet been isolated from patients with Lyme borreliosis. 55, 56 There is a newly described uncultivable Borrelia species, Borrelia lonestarii, which has been found in the Lone Star tick, Amblyomma americanum, and may be associated with Lyme-like disease in the southern United States. To Certain genospecies have been associated more frequently with certain clinical manifestations. 10, 74-76 B. lonestarii and a new species, Borrelia miyamotoi, 77 may be more closely related to the relapsing fever borreliae than to B. burgdorferi sensu lato. 73, 77

## Borrelia burgdorferi as the Etiologic Agent of Lyme Borreliosis

In 1981, Burgdorfer and associates discovered (isolated) a new species of Borrelia in Ixodes dammini (later re-

named *Ixodes scapularis*<sup>78</sup>) ticks from a Lyme-endemic area in New York, demonstrated elevated antibody titers to this spirochete in convalescent sera of patients with Lyme disease, and proposed that this spirochete was involved in the etiology of Lyme disease.<sup>1, 17</sup>

In 1982, Berger and colleagues demonstrated rare spirochetes, similar to the *I. dammini (scapularis)* spirochete, by Warthin-Starry silver stain in skin biopsy specimens of untreated patients with EM skin lesions; they were able to isolate spirochetes from one specimen, thus supporting a spirochetal etiology for EM.<sup>79</sup> In 1985, Berger and co-workers grew the *I. dammini (scapularis)* spirochete from several skin biopsy specimens of EM lesions<sup>79</sup> and thus confirmed this spirochete as the etiologic agent of North American EM.

In 1983, Steere and associates isolated the new spirochete, which was subsequently named *Borrelia burg*dorferi, from blood, spinal fluid, and joint fluid of American Lyme disease patients and from *I. dammini* (scapularis) ticks in a Lyme-endemic area of Connecticut; they

# CASES OF LYME DISEASE REPORTED TO THE CDC, 1982-1998, UNITED STATES




FIGURE 11-3 The number of cases of Lyme disease in the United States reported to the CDC by the individual state health departments has increased steadily from 1982 to 1998.<sup>4, 461</sup> Lyme disease became a reportable disease in 1990.<sup>3</sup>

demonstrated serum IgM and IgG antibody titer increases in these patients directed against this spirochete. Simultaneously in 1983, Benach and colleagues isolated the same spirochete from the blood of patients with American Lyme disease and demonstrated similar seropositivity in these patients. Doth groups proposed the I. dammini (scapularis) spirochete as the etiologic agent of Lyme disease. In the same year, Barbour and co-workers, including Burgdorfer, isolated a new spirochete, similar to the I. dammini (scapularis) spirochete, from Ixodes ricinus ticks from an EM-endemic area of Switzerland.

Ryberg and associates, including Burgdorfer, in 1983 demonstrated significant levels of IgM and IgG serum antibodies against the North American Lyme disease spirochete in sera of European patients with lymphocytic meningoradiculitis (Bannwarth's syndrome); they proposed the Lyme disease spirochete as the etiologic

agent of Bannwarth's syndrome.21

In 1984 and 1985, Asbrink, Hovmark, and colleagues isolated the *I. ricinus* spirochete from skin biopsy specimens of European patients with EM,<sup>19</sup> acrodermatitis chronica atrophicans,<sup>19, 20</sup> and lymphadenosis benigna cutis<sup>22</sup>; antibody titer elevations against this spirochete were demonstrated in these patients, thus confirming the spirochetal etiology of these European skin diseases. In 1987, de Koning and co-workers demonstrated spirochetes, morphologically consistent with *B. burgdorferi*, in European EM and lymphadenosis benigna cutis skin lesions, in synovia of patients with European Lyme arthritis, and in spinal fluid of a patient with European Bannwarth's syndrome, and thus confirmed the spirochetal etiology of these additional European diseases.<sup>82</sup>

Some genospecies, such as B. burgdorferi sensu stricto, garinii, and afzelii, have been associated with human Lyme borreliosis, and others, such as B. japonica, only with tick vectors and reservoir hosts but not yet with human disease. 55, 56 B. valaisiana DNA has been found in EM lesions of two patients by PCR72; B. burgdorferi sensu lato isolates similar to strain 25015 of group DN127 were found in the cerebrospinal fluid (CSF) and EM of nine Slovenian patients 83, 884; and B. burgdorferi genospecies DN127 was isolated from one patient with borrelial

lymphocytoma.74

There is clustering of genospecies from patients with different clinical manifestations, such as EM, ACA, neuroborreliosis, arthritis, and carditis<sup>55, 67, 74–76, 84–89</sup>; this clustering suggests the possibility of differences in pathogenicity and organotropism of strains of different phenotypes and genotypes, which may be related to differences in clinical syndromes associated with these strains.<sup>51–53</sup>

In North America, where ACA does not occur, B. burgdorferi sensu stricto is the only agent of human Lyme disease, and is associated with all North American manifestations of Lyme disease, EM, neuroborreliosis, arthritis, and carditis. In Europe, ACA is associated predominantly with B. afzelii, and occasionally with garinii or sensu stricto<sup>67, 74–76, 85–87, 89</sup>; EM with all three genospecies (B. burgdorferi sensu stricto, garinii, afzelii)<sup>74–76, 85, 89</sup>; neuroborreliosis predominantly but not exclusively with B. garinii<sup>74–76, 85, 87, 88</sup>; arthritis predominantly with sensu

stricto and sometimes with garinii75, 76; and carditis with sensu stricto and occasionally with garinii.75, 76

Within genospecies, there may be strains that are more pathogenic than others, as may be involved in the clustering of strains isolated from European patients with disseminated Lyme borreliosis in one sub-branch of B. garinii, 55 the clustering of B. garinii strains associated with adult neuroborreliosis in Osp A serotype 4, and the clustering of garinii associated with pediatric neuroborreliosis in Osp A serotype 6.88

A large study by the EUCALB, of over 2000 patients with Lyme borreliosis in 15 European countries during 12 months in 1994, found that the incidence of Lyme borreliosis per 100,000 population increased from Western to Eastern Europe, with higher incidences east of

the Netherlands, France, and Italy.10

### Morphology

Borrelia burgdorferi<sup>56, 81, 91–98, 218</sup> is a long (10 to 30 micrometers in length), narrow (0.18 to 0.25 micrometer in diameter), irregularly and loosely coiled, helical, motile, flexible spirochete with tapered ends and sheathed flagellae.

It has an inner and an outer cell membrane and four to eight flagellae, located in the periplasmic space between the inner and outer trilaminar cell membranes. These membranes, which are inserted at each end and extend toward the middle of the spirochete, allow it to move efficiently through viscous solutions and presumably enhance its ability to disseminate in body tissues. The trilaminar outer membrane structure is similar to, but more fluid than, that of gram-negative bacteria, and it contains the embedded outer surface membrane lipoproteins and a lipopolysaccharide with weak endotoxin-like activity. The flexible cell wall is located just outside the cytoplasmic membrane. In addition to the typical B. burgdorferi morphology, morphologic variants have been found in tissue biopsies.

# Molecular Biology

B. burgdorferi has several major antigens that can be separated by polyacrylamide gel electrophoresis and characterized antigenically by reactivity in Western blots with B. burgdorferi—specific polyclonal and monoclonal antibodies, 51, 52, 92, 93, 104, 105

The 83- to 100-kilodalton (kd) antigen p83/100 is Borrelia genus-specific, 51, 106, 107 cross reacts minimally with other bacteria, 104 is associated with either the flagella or the protoplasmic cylinder, and is a chromosomally encoded immunodominant antigen of B. burgdorferi sensu lato, which has minor homology with the muscle and cytoskeletal proteins myosin and troponin, and contains an amino acid sequence that is a common cell recognition signal of integrins and may be involved in spirochetal attachment to cells. 105 The constant-molecular-weight, major immunodominant 60-kd common antigen HSP60, and the 70-kd antigen HSP70 are heat shock proteins that function as flagellin chaperones, are encoded by chromosomal genes, and cross react broadly with other bacteria. 104, 109, 882 The 35-kd protein, a B.

burgdorferi sensu lato-specific lipoprotein encoded by a chromosomal gene, is expressed early in human infection and is an important immunodominant marker for early human infection.110 There are several other significant antigens, including the 39-kd molecular weight protein, some encoded by chromosomal and some by

plasmid genes.882

The 41-kd flagellar antigen p41 is the other major protein of the organism51, 52, it has a uniform molecular weight in all B. burgdorferi strains,51 is encoded by a highly conserved gene (with 96-97% sequence homology between strains) located on the main chromosome,111 and is the antigen most often recognized in Lyme borreliosis patient sera. 112 B. burgdorferi flagellin has an epitope that shares amino acid homology with the N-terminal amino acid sequences of human chaperonin, a 60-kd heat shock protein,113 and has some cross-

reactivity with other spirochetes.

B. burgdorferi has several major outer surface lipoproteins—Osp A,114 Osp B,114 Osp C,114, 116 Osp D,117 Osp E,118 Osp F,118 and pG119—that are encoded by plasmids. 114, 120, 882 The 18-kd EppA protein (exported plasmid protein A) is thought to be either an outer membrane or a secreted protein.121 Osp A has the least variability and the greatest homology (77-83%) of the three major B. burgdorferi genospecies 108, 114, 122; Osp B has high variability 114; and Osp C has the highest variability and exhibits polymorphism of its amino acid sequences and Osp C-encoding gene sequences. 114, 120, 123 Osp C is expressed early in infection, 124, 125 and, despite this heterogeneity, the three major genospecies have common as well as genospecies-specific Osp C immunogenic epitopes recognized by patient sera. 108, 125 Osp A has an immunodominant epitope that shares amino acid sequence homology and encoding DNA sequence homology with human leukocyte function-associated antigen-1 (LFA-1), which is a candidate arthritogenic autoantigen that may be involved in the immunopathogenesis of Lyme arthritis. 126

The smaller, variable-molecular-weight outer surface membrane lipoproteins of B. burgdorferi are species-specific, and antigenic modulation, variation in size, antigenicity, and expression of these outer surface proteins have been found. 51, 52, 92, 93, 129, 130 In 1998, Kawabata and associates reported that B. burgdorferi sensu stricto strain 297 has VMP-like proteins coded by VMP-like sequences (VIs) located in multiple copies on the 20 kilobase pair plasmid.130 In 1997, Zhang and colleagues described a system in B. burgdorferi sensu stricto strain B31 that produces extensive antigenic variability in a surface lipoprotein.131 B. burgdorferi Vls is expressed in patients with Lyme borreliosis,130 and the system of antigenic variability may enhance evasion of the host

immune response.130, 131

B. burgdorferi also has nonprotein antigens, composed of lipid-carbohydrate-, and phosphorus-containing compounds, which react with Lyme disease patient sera but

are of unknown significance.132 The genome of B. burgdorferi has been sequenced. 133, 882 B. burgdorferi sensu stricto strain B31 has a large linear chromosome of 910, 725 base pairs (about 900 kbp) and at least 17 plasmids (10 linear plasmids

ranging in size from 17 to 56 kbp, and 7 circular plasmids ranging from 9 to 32 kbp) with a combined total of 533,000 base pairs (about 500 kbp) of double-stranded DNA with an average G plus C content of 28.6%.882 The linear chromosome has been sequenced and contains 853 genes that encode proteins needed for DNA replication, transcription, translation, energy metabolism, and solute transport, but not for cellular biosynthesis. Eleven of the plasmids (ranging from about 9 to 54 kbp in size), containing 430 genes, have been sequenced. The functions of most of these genes are unknown, but they may be involved in antigenic variation and immune evasion; some, such as the 53- to 58-kbp linear plasmid in B. burgdorferi sensu stricto, garinii, and afzelii, and the 90- to 105-kbp linear plasmid in B. japonica, encode outer surface proteins A and B. Others, such as the 26to 27-kbp circular plasmid, encode Osp C. Fifty-nine percent of the chromosomal genes have known biologic roles, 12% match genes in other organisms with unknown roles, and 29% are new genes; these percentages for plasmid genes are 16, 26, and 58, respectively.882 Almost all of the membrane proteins of B. burgdorferi are lipoproteins, and 8% of its genes encode 105 putative lipoproteins, which is a much greater percentage than occurs with most other bacteria; six percent of the genes encode proteins involved in spirochetal motility and chemotaxis.882

Although North American and European B. burgdorferi sensu stricto isolates tend to cluster into separate subbranches by DNA analysis,55 there are genetic similarities between some isolates from the two continents, suggesting some previous interchange of strains between

the two continents.62

Among the different genospecies, 657, 117, 134 there are differences in the number, size, and sequences of the linear and circular plasmids, as well as their presence or absence, which correlate with the expression of the outer surface proteins they encode. The Osp A- and Osp B-encoding linear plasmid is present in all B. burgdorferi sensu lato genospecies (although some individual isolates may lack the Osp B gene, and this plasmid may be lost in culture). Almost all North American and European strains express Osp A and it shows the least antigenic variability between genospecies120; Osp A serotyping has been used to divide B. burgdorferi sensu lato into different phenotypes, 105 which correlate with different genotypes by Osp A gene sequencing. The Osp C gene is located, on a 26-kbp circular plasmid that is present in all genospecies, but its expression, both qualitatively and quantitatively, is variable; most European strains express Osp C, but Osp C has been found to be cryptic in North American strains, where it is expressed only in strains that have lost all plasmids other than the Osp Cencoding and Osp AB-encoding plasmids.116 The Osp D gene is highly conserved and is present in 24, 50, and 90%, respectively, of isolates of B. burgdorferi sensu stricto, afzelii, and garinii; its encoding plasmid has significant size variability, ranging from 36 to 40 kbp, and contains varying numbers of copies of a 17-kbp repeating sequence bordering a variable region with evidence of homologous recombinational events.117 The Osp E and Osp F genes are located in tandem on the

45-kbp linear plasmid.118 The pG gene is located on a 48-kbp linear plasmid that has some sequence homology to the Osp EF gene and is detectable in most strains of B. burgdorferi sensu stricto and B. afzelii, but not in B. garinii or B. japonica. 119 There is p83/100 gene heterogeneity in B. garinii, but not in either B. burgdorferi sensu stricto or B. afzelii; B. garinii strains could be separated into two major subtypes on the basis of p83/100 gene sequence variation, one corresponding to Osp A serotype 4 and the other to serotypes 3, 5, 6, and 7.106 The EppA protein gene is located on the 9-kbp circular plasmid, and loss of this plasmid has been associated with loss of virulence during passage of B. burgdorferi in

It has been proposed that the high level of variability of Osp C115 and D,117 and the existence of a VMP-like system130, 131 may be involved in immune evasion by B. burgdorferi. Evasion of the immune response by a B. burgdorferi strain expressing a truncated Osp B also raised this as a possible immune escape mechanism. 135, 136

Differential gene expression, which has been found in B. burgdorferi, has also been suspected to be involved in infectivity, invasion, and dissemination, and in evasion of the host immune response to the infection120, 137; it may also have a role in differential organotropism. Abundant Osp A and Osp B, and no Osp C, are expressed by B. burgdorferi in unfed tick midguts. The beginning of tick feeding and the arrival of the blood meal in the tick midgut trigger downregulation of Osp A and B, and upregulation of Osp C expression of B. burgdorferi in the engorged tick midgut. 138-140 Although Osp A and B are not expressed initially after infection, they are eventually expressed, in particular in patients with chronic Lyme arthritis. Although Osp E and Osp F are expressed by B. burgdorferi in ticks and in the mammalian host, it appears that the Osp E and F homologues, the Erp proteins (Osp EF-related proteins), form a gene group that is differentially expressed at different stages of the spirochete's life cycle; the Osp E homologue, p21, which has 70% amino acid homology with Osp E, and the Osp F homologues, pG, bbk2.10, and bbk2.11, are expressed only in the mammalian host and not in the spirochete in culture or in ticks. 119, 127, 141 Expression of p21 does not occur even in engorged ticks, only in the mammalian host; antibody to p21 is found in 28 to 33% of patients with early or late Lyme disease, including Lyme arthritis, indicating its expression during Lyme disease. 127 Confirmation of differential gene expression during Lyme disease was first reported in 1998, when p35 (the 35-kd protein) and p37 (the 37kd protein) messenger RNA (mRNA), but not Osp A mRNA, was found in EM skin biopsies and Lyme arthritis synovium, consistent with upregulation of p35 and p37 and the downregulation of Osp A.141 The protein EppA (exported plasmid protein A) is downregulated at the transcriptional level in cultured B. burgdorferi, is expressed only in the mammalian host, and is associated with virulent strains of B. burgdorferi. 121 Temperature increases, as occur with ingestion of the blood meal by the tick, and even increases in culture temperature from 23° C to 35° C, induce downregulation of Osp A expression, and upregulation of Osp C, Osp E, Osp F, and of

the Osp EF homologues, the Erp proteins. 128, 140, 142 As Osp A is downregulated and disappears, the spirochete becomes resistent to antibody against Osp A; this is important in vaccine development, as is discussed in the

section Prevention: Vaccine Development.

B. burgdorferi produces none of its own proteolytic enzymes. It acquires a host-derived activated proteolytic complex consisting of plasmin, plasminogen, and a urokinase-type plasminogen activator, which arrives at the tick midgut in the blood meal, binds to Osp A while it is still expressed, and coats the spirochete; this complex is presumably able to dissolve extracellular matrix, facilitate dissemination of the spirochete to the tick salivary glands for transmission to the host, and then enhance spirochete dissemination in host tissues, where the hostderived antigens cause the spirochete to be invisible immunologically to the host. 143-146 Surface antigens of B. burgdorferi, particularly Osp A, are also involved in binding of the spirochete to collagen fibers, vascular endothelium, and other cells,147 including antigen-presenting cells,148 and in triggering a variety of events in host cells, ranging from expression of adhesion molecules to production of cytokines and other factors involved in the immunopathogenesis of the infection, 149, 150 as is discussed in the section Pathology and Pathogenesis.

Some antigens of B. burgdorferi have epitopes that share homology and cross react with host epitopes, leading to molecular mimicry,151 such as B. burgdorferi Osp A and human leukocyte function-associated antigen-1 (LFA-1),126 and possibly p83/100 and the human muscle and cytoskeletal proteins myosin and troponin, 106 B. burgdorferi flagellin, and human axonal heat shock protein 60.113 This is discussed further in the sections Pathology and Pathogenesis, and Interactions with the Immune System: Correlation of Clinical Manifestations with

HLA Type.

### Taxonomy

Borrelia burgdorferi,51,94 the etiologic agent of Lyme borreliosis, is a member of the order Spirochaetales, the family Spirochaetaceae, the genus Borrelia, and the species burgdorferi. Borreliae are more closely related genetically to Spirochaeta than to Treponema, and all borreliae

are transmitted by arthropods.99

B. burgdorferi was initially divided into four phenotypes,92 and later into eight serotypes31, 52, 105, 259 on the \* basis of antigenic diversity of Osp A as determined by reactivity with various monoclonal antibodies and by Osp A gene sequencing. 105 It was also initially divided into three genotype subspecies, based on DNA homology and ribosomal RNA restriction endonuclease pattern analysis,50,53 and corresponding to phenotypes based on major protein antigenicity, with 76 to 100% DNA homology within groups, and 46 to 74% between

As more isolates of B. burgdorferi have been studied by various methods, it has become clear that B. burgdorferi has phenotypic and genotypic heterogeneity.\* On the basis of phenotypic and genotypic differences from

<sup>\*</sup>See references 13, 51-66, 68, 70, 100, 105, 115, 117, 123, and 884.